Glofitamab (Columvi®) will now be offered to around 300 people a year thanks to fast-tracking through the Cancer Drugs Fund (CDF), which provides patients with quicker access to the latest innovative cancer therapies.

Professor Peter Johnson, NHS England's national clinical director for cancer, said: ‘Antibodies such as glofitamab that harness the power of the immune system to target lymphoma, are transforming the way people are treated and helping to boost the number of people cured.

‘This is excellent news for patients with this aggressive form of blood cancer, with the NHS fast-tracking this cutting-edge treatment so that more people can benefit.'

The CDF is now helping around 1,000 patients every month to access new treatments faster, with more than 108,000 patients being offered the latest cancer medicines on the NHS since its introduction in July 2016.

Over 300 cancer treatment approvals have been fast-tracked via the CDF, with 50 new options added in the past 18 months.